Candida lusitaniae MICs to the echinocandins are elevated but FKS-mediated resistance is rare

Diagnostic Microbiology and Infectious Disease

Volumn 84, Issue 1, 2016, Pages 52-54

  Lockhart, Shawn R ^a   Pham, Cau D ^a   Kuykendall, Randall J ^a   Bolden, Carol B ^a   Cleveland, Angela A ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Candida lusitaniae; Echinocandin; Epidemiological cutoff value; FKS

Indexed keywords

ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; MICAFUNGIN; ANTIFUNGAL AGENT; GLUCOSYLTRANSFERASE;

ANTIFUNGAL RESISTANCE; ARTICLE; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CLAVISPORA LUSITANIAE; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; EPIDEMIOLOGIC CUTOFF VALUE; FKS1 GENE; FUNGAL GENE; FUNGUS ISOLATION; GENE SEQUENCE; MEYEROZYMA GUILLIERMONDII; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; REFERENCE VALUE; WILD TYPE; CANDIDA; DNA SEQUENCE; DRUG EFFECTS; ENZYMOLOGY; GENETICS; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST;

ANTIFUNGAL AGENTS; CANDIDA; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; GLUCOSYLTRANSFERASES; HUMANS; MICROBIAL SENSITIVITY TESTS; SEQUENCE ANALYSIS, DNA;

EID: 84949320290     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2015.08.012     Document Type: Article

References (28)

1. Cleveland A.A., Farley M.M., Harrison L.H., Stein B., Hollick R., Lockhart S.R., et al. Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011. Clin Infect Dis 2012, 55:1352-1361.
2. Clinical and Laboratory Standards Institute (CLSI) Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard-third edition; CLSI document M27-A3 2008, CLSI, Wayne, PA.
3. Clinical and Laboratory Standards Institute (CLSI) M27-S4 reference method for broth dilution antifungal susceptibility testing of yeasts; fourth informational supplement 2012, CLSI, Wayne, PA.
4. Desnos-Ollivier M., Moquet O., Chouaki T., Guerin A.M., Dromer F. Development of echinocandin resistance in Clavispora lusitaniae during caspofungin treatment. J Clin Microbiol 2011, 49:2304-2306.
5. Diekema D.J., Messer S.A., Boyken L.B., Hollis R.J., Kroeger J., Tendolkar S., et al. In vitro activity of seven systemically active antifungal agents against a large global collection of rare Candida species as determined by CLSI broth microdilution methods. J Clin Microbiol 2009, 47:3170-3177.
6. Espinel-Ingroff A., Aller A.I., Canton E., Castanon-Olivares L.R., Chowdhary A., Cordoba S., et al. Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole. Antimicrob Agents Chemother 2012, 56:5898-5906.
7. Espinel-Ingroff A., Arendrup M.C., Pfaller M.A., Bonfietti L.X., Bustamante B., Canton E., et al. Interlaboratory variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST methods: should the clinical laboratory be testing this agent?. Antimicrob Agents Chemother 2013, 57:5836-5842.
8. Espinel-Ingroff A., Chakrabarti A., Chowdhary A., Cordoba S., Dannaoui E., Dufresne P., et al. Multicenter evaluation of MIC distributions for epidemiologic cutoff value definition to detect amphotericin B, posaconazole, and itraconazole resistance among the most clinically relevant species of Mucorales. Antimicrob Agents Chemother 2015, 59:1745-1750.
9. Espinel-Ingroff A., Pfaller M.A., Bustamante B., Canton E., Fothergill A., Fuller J., et al. Multilaboratory study of epidemiological cutoff values for detection of resistance in eight Candida species to fluconazole, posaconazole, and voriconazole. Antimicrob Agents Chemother 2014, 58:2006-2012.
10. Falagas M.E., Roussos N., Vardakas K.Z. Relative frequency of albicans and the various non-albicans Candida spp among candidemia isolates from inpatients in various parts of the world: a systematic review. Int J Infect Dis 2010, 14:e954-e966.
11. Faria-Ramos I., Neves-Maia J., Ricardo E., Santos-Antunes J., Silva A.T., Costa-de-Oliveira S., et al. Species distribution and in vitro antifungal susceptibility profiles of yeast isolates from invasive infections during a Portuguese multicenter survey. Eur J Clin Microbiol Infect Dis 2014, 33:2241-2247.
12. Hidron A.I., Edwards J.R., Patel J., Horan T.C., Sievert D.M., Pollock D.A., et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008, 29:996-1011.
13. Lockhart S.R., Iqbal N., Cleveland A.A., Farley M.M., Harrison L.H., Bolden C.B., et al. Species identification and antifungal susceptibility testing of Candida bloodstream isolates from population-based surveillance studies in two U.S. cities from 2008 to 2011. J Clin Microbiol 2012, 50:3435-3442.
14. Lyon G.M., Karatela S., Sunay S., Adiri Y. Antifungal susceptibility testing of Candida isolates from the Candida surveillance study. J Clin Microbiol 2010, 48:1270-1275.
15. Montagna M.T., Lovero G., Borghi E., Amato G., Andreoni S., Campion L., et al. Candidemia in intensive care unit: a nationwide prospective observational survey (GISIA-3 study) and review of the European literature from 2000 through 2013. Eur Rev Med Pharmacol Sci 2014, 18:661-674.
16. Orasch C., Marchetti O., Garbino J., Schrenzel J., Zimmerli S., Muhlethaler K., et al. Candida species distribution and antifungal susceptibility testing according to European Committee on Antimicrobial Susceptibility Testing and new vs. old Clinical and Laboratory Standards Institute clinical breakpoints: a 6-year prospective candidaemia survey from the fungal infection network of Switzerland. Clin Microbiol Infect 2014, 20:698-705.
17. Pfaller M.A., Andes D., Diekema D.J., Espinel-Ingroff A., Sheehan D. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist Updat 2010, 13:180-195.
18. Pfaller M.A., Andes D.R., Diekema D.J., Horn D.L., Reboli A.C., Rotstein C., et al. Epidemiology and outcomes of invasive candidiasis due to non-albicans species of Candida in 2,496 patients: data from the Prospective Antifungal Therapy (PATH) registry 2004-2008. PLoS One 2014, 9:e101510.
19. Pfaller M.A., Boyken L., Hollis R.J., Kroeger J., Messer S.A., Tendolkar S., et al. Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp. J Clin Microbiol 2010, 48:52-56.
20. Pfaller M.A., Castanheira M., Diekema D.J., Messer S.A., Jones R.N. Triazole and echinocandin MIC distributions with epidemiological cutoff values for differentiation of wild-type strains from non-wild-type strains of six uncommon species of Candida. J Clin Microbiol 2011, 49:3800-3804.
21. Pfaller M.A., Diekema D.J. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007, 20:133-163.
22. Pfaller M.A., Espinel-Ingroff A., Bustamante B., Canton E., Diekema D.J., Fothergill A., et al. Multicenter study of anidulafungin and micafungin MIC distributions and epidemiological cutoff values for eight Candida species and the CLSI M27-A3 broth microdilution method. Antimicrob Agents Chemother 2014, 58:916-922.
23. Pfaller M.A., Espinel-Ingroff A., Canton E., Castanheira M., Cuenca-Estrella M., Diekema D.J., et al. Wild-type MIC distributions and epidemiological cutoff values for amphotericin B, flucytosine, and itraconazole and Candida spp. as determined by CLSI broth microdilution. J Clin Microbiol 2012, 50:2040-2046.
24. Pfaller M.A., Messer S.A., Moet G.J., Jones R.N., Castanheira M. Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in intensive care unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009). Int J Antimicrob Agents 2011, 38:65-69.
25. Pfaller M., Neofytos D., Diekema D., Azie N., Meier-Kriesche H.U., Quan S.P., et al. Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance(R)) registry, 2004-2008. Diagn Microbiol Infect Dis 2012, 74:323-331.
26. Turnidge J., Kahlmeter G., Kronvall G. Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values. Clin Microbiol Infect 2006, 12:418-425.
27. Wisplinghoff H., Ebbers J., Geurtz L., Stefanik D., Major Y., Edmond M.B., et al. Nosocomial bloodstream infections due to Candida spp. in the USA: species distribution, clinical features and antifungal susceptibilities. Int J Antimicrob Agents 2014, 43:78-81.
28. Zimbeck A.J., Iqbal N., Ahlquist A.M., Farley M.M., Harrison L.H., Chiller T., et al. FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from U.S. population-based surveillance. Antimicrob Agents Chemother 2010, 54:5042-5047.